
WHEREAS, Due to its prevalence, CMV is the virus most
frequently transmitted by an infected mother to a child before
or during birth; and
WHEREAS, Each year in the United States, approximately 1 in
every 200 children is born with congenital CMV, causing an
estimated 400 deaths and leaving approximately 6,000 children
with permanent disabilities such as hearing or vision loss or
intellectual disabilities; and
WHEREAS, Roughly 10% of babies born with congenital CMV are
symptomatic at birth, while the overwhelming majority do not
present any symptoms as a newborn; and
WHEREAS, More children are adversely affected by congenital
CMV than by several better-known childhood diseases or syndromes
such as Down syndrome, fetal alcohol syndrome, neural tube
defects, such as spina bifida, and pediatric HIV/AIDS; and
WHEREAS, Congenital CMV infection is more common than the 35
combined metabolic and endocrine disorders on the Recommended
Uniform Screening Panel (RUSP) for newborns; and
WHEREAS, Screening for congenital CMV can only occur within
the first 21 days of life by screening newborns for CMV in the
saliva, urine or both; and
WHEREAS, Congenital CMV screening was nominated for
consideration to be included on the RUSP in March 2019; and
WHEREAS, In the United States, only 9% of women have heard of
CMV, compared with 97% who have heard of Down syndrome and 98%
who have heard of HIV/AIDS; and
WHEREAS, Every woman of childbearing age should know her CMV
status by asking her doctor for a CMV blood test; and
WHEREAS, To prevent CMV, women should avoid saliva and other
bodily fluids of children under six years of age and practice
20190HR0360PN1923 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30